



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/734,585	12/15/2003	Michael Bock	EFFERT-1	1385
23599	7590	11/02/2005	EXAMINER	
MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE 1400 ARLINGTON, VA 22201			RAMIREZ, JOHN FERNANDO	
		ART UNIT	PAPER NUMBER	
			3737	

DATE MAILED: 11/02/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

TAK

Office Action Summary	Application No.	Applicant(s)
	10/734,585	BOCK ET AL.
	Examiner	Art Unit
	John F. Ramirez	3737

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 12/15/03.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-15 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-15 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 12/15/03 is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 - 1) Certified copies of the priority documents have been received.
 - 2) Certified copies of the priority documents have been received in Application No. _____.
 - 3) Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>09/09/04 -10/29/04</u> .	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

Priority

Applicant is advised of possible benefits under 35 U.S.C. 119(a)-(d), wherein an application for patent filed in the United States may be entitled to the benefit of the filing date of a prior application filed in a foreign country.

Accordingly, the examiner of record respectfully requests the submittal of the translation of the foreign document, GERMAN PATENT No. 102 603 72.3

Specification

The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use. Correction is needed.

Content of Specification

- (a) Title of the Invention: See 37 CFR 1.72(a) and MPEP § 606. The title of the invention should be placed at the top of the first page of the specification unless the title is provided in an application data sheet. The title of the invention should be brief but technically accurate and descriptive, preferably from two to seven words may not contain more than 500 characters.
- (b) Cross-References to Related Applications: See 37 CFR 1.78 and MPEP § 201.11.
- (c) Statement Regarding Federally Sponsored Research and Development: See MPEP § 310.

Art Unit: 3737

(d) The Names Of The Parties To A Joint Research Agreement: See 37 CFR 1.71(g).

(e) Incorporation-By-Reference Of Material Submitted On a Compact Disc: The specification is required to include an incorporation-by-reference of electronic documents that are to become part of the permanent United States Patent and Trademark Office records in the file of a patent application. See 37 CFR 1.52(e) and MPEP § 608.05. Computer program listings (37 CFR 1.96(c)), "Sequence Listings" (37 CFR 1.821(c)), and tables having more than 50 pages of text were permitted as electronic documents on compact discs beginning on September 8, 2000.
Or alternatively, Reference to a "Microfiche Appendix": See MPEP § 608.05(a). "Microfiche Appendices" were accepted by the Office until March 1, 2001.

(f) Background of the Invention: See MPEP § 608.01(c). The specification should set forth the Background of the Invention in two parts:

- (1) Field of the Invention: A statement of the field of art to which the invention pertains. This statement may include a paraphrasing of the applicable U.S. patent classification definitions of the subject matter of the claimed invention. This item may also be titled "Technical Field."
- (2) Description of the Related Art including information disclosed under 37 CFR 1.97 and 37 CFR 1.98: A description of the related art known to the applicant and including, if applicable, references to specific related art and problems involved in the prior art which are solved by the applicant's invention. This item may also be titled "Background Art."

(g) Brief Summary of the Invention: See MPEP § 608.01(d). A brief summary or general statement of the invention as set forth in 37 CFR 1.73. The summary is separate and distinct from the abstract and is directed toward the invention rather than the disclosure as a whole. The summary may point out the advantages of the invention or how it solves problems previously existent in the prior art (and preferably indicated in the Background of the Invention). In chemical cases it should point out in general terms the utility of the invention. If possible, the nature and gist of the invention or the inventive concept should be set forth. Objects of the invention should be treated briefly and only to the extent that they contribute to an understanding of the invention.

Art Unit: 3737

- (h) Brief Description of the Several Views of the Drawing(s): See MPEP § 608.01(f). A reference to and brief description of the drawing(s) as set forth in 37 CFR 1.74.
- (i) Detailed Description of the Invention: See MPEP § 608.01(g). A description of the preferred embodiment(s) of the invention as required in 37 CFR 1.71. The description should be as short and specific as is necessary to describe the invention adequately and accurately. Where elements or groups of elements, compounds, and processes, which are conventional and generally widely known in the field of the invention described and their exact nature or type is not necessary for an understanding and use of the invention by a person skilled in the art, they should not be described in detail. However, where particularly complicated subject matter is involved or where the elements, compounds, or processes may not be commonly or widely known in the field, the specification should refer to another patent or readily available publication which adequately describes the subject matter.
- (j) Claim or Claims: See 37 CFR 1.75 and MPEP § 608.01(m). The claim or claims must commence on separate sheet or electronic page (37 CFR 1.52(b)(3)). Where a claim sets forth a plurality of elements or steps, each element or step of the claim should be separated by a line indentation. There may be plural indentations to further segregate subcombinations or related steps. See 37 CFR 1.75 and MPEP § 608.01(i)-(p).
- (k) Abstract of the Disclosure: See MPEP § 608.01(f). A brief narrative of the disclosure as a whole in a single paragraph of 150 words or less commencing on a separate sheet following the claims. In an international application which has entered the national stage (37 CFR 1.491(b)), the applicant need not submit an abstract commencing on a separate sheet if an abstract was published with the international application under PCT Article 21. The abstract that appears on the cover page of the pamphlet published by the International Bureau (IB) of the World Intellectual Property Organization (WIPO) is the abstract that will be used by the USPTO. See MPEP § 1893.03(e).
- (l) Sequence Listing, See 37 CFR 1.821-1.825 and MPEP §§ 2421-2431. The requirement for a sequence listing applies to all sequences disclosed in a given application, whether the sequences are claimed or not. See MPEP § 2421.02.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-15 are rejected under 35 U.S.C. 102(e) as being anticipated by Foo et al. (US 6,408,201).

Foo et al. substantially discloses all claimed features in claims 1-15.

Concerning to Claims 1-8, Foo et al. discloses a nuclear spin tomography device to obtain data for locally-resolved imaging of the magnetic resonance behavior of the atomic nuclei in a selected field of view in a body, the device being made and programmed such that the body can be exposed by the device to high frequency and magnetic field gradient echo pulse sequences that produce magnetization in a body such that the magnetization of a medium that is flowing in at least one direction in space in the body can be attenuated by dephasing the spins of the atomic nuclei in the medium, and an MR contrast medium that is taken up by the body (Abstract),

magnetization of the medium flowing in at least one direction in space in the body can be attenuated by dephasing of the spins by gradient moments of order $i M_i(t)$ being maximized in this direction in space according to the following relation:

$$M_i(t) = \gamma \cdot \int_0^t G(t') \cdot t'^i dt'$$

whereby, i is an integer greater than zero, γ is the gyromagnetic ratio of the atomic nuclei, $G(t')$ is a time-dependent gradient field intensity in this direction in space and t is the time interval that has passed since the emission of a high frequency pulse for excitation of the atomic nuclei (col. 3, lines 31-49; col. 9 line 19 – col. 12, line 50), wherein the magnetization of the medium flowing in at least one direction in space in the body can be attenuated by dephasing of the spins in that gradient moments of the first order $M_1(t)$ are maximized in this direction in space according to the following relation (col. 3, lines 31-49; col. 9 line 19 – col. 12, line 50):

$$M_1(t) = \gamma \cdot \int_0^t G(t') \cdot t' dt'$$

, wherein gradient echo pulse sequences can be produced in the respective directions in space by inserting the flow dephasing gradient pulses into flow-compensated imaging gradient echo pulse sequences (col. 3, lines 31-49), wherein M_1 satisfies the following relation: $M_1(t; G_{bipolar}, tramp, tplateau, tsep) = \gamma \cdot G_{bipolar} \cdot (tramp + tplateau) \cdot (2tramp + tplateau + tsep)$ (Figure 4, col. 7, line 61 – col. 9, line 18), wherein the device

Art Unit: 3737

is a static magnet, gradient devices for producing gradient pulses in three directions in space that are orthogonal to one another (col. 7, lines 60-67), a transmission device for producing high frequency signals, a receiving device for high frequency signals, a device for triggering gradient devices and the transmission device, an evaluation device, and a display device (Fig. 1), wherein the MR contrast medium can be administered intravenously to a human or animal body (col. 7, lines 24-34), wherein the MR contrast medium is lymph-passable and/or plaque-passable (Abstract).

In regards to claims 9-15, Foo et al. teaches all the structures as set forth above. The process concerning the steps of (1) locally-resolved imaging of the magnetic resonance behavior of the atomic nuclei in a selected field of view in a body, (2) the device being made and programmed such that the body can be exposed by the device to high frequency and magnetic field gradient echo pulse sequences that produce magnetization in a body such that the magnetization of a medium that is flowing in at least one direction in space in the body can be attenuated by dephasing the spins of the atomic nuclei in the medium, (3) an MR contrast medium that is taken up by the body, (4) magnetization of the medium flowing in at least one direction in space in the body can be attenuated by dephasing of the spins by gradient moments of order $i M_i(t)$ being maximized in this direction in space, (5) gradient echo pulse sequences can be produced in the respective directions in space by inserting the flow dephasing gradient pulses into flow-compensated imaging gradient echo pulse sequences, (6) wherein M_1 satisfies the following relation: $M_1(t; G_{bipolar}, tramp, tplateau, tsep) = \gamma \bullet G_{bipolar} \bullet (tramp + tplateau) \bullet (2tramp + tplateau + tsep)$, (7) wherein the MR contrast medium

can be administered intravenously to a human or animal body, (8) wherein the MR contrast medium is lymph-passable and/or plaque-passable, would be inherently met by the disclosure.


Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John F. Ramirez whose telephone number is (571) 272-8685. The examiner can normally be reached on (Mon-Fri) 7:30 - 4:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian L. Casler can be reached on (571) 272-4956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JFR
10/31/05


BRIAN L. CASLER
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700